Skip to content

Questionnaire study to identify initial symptoms and processes leading up to diagnosis in metastatic breast cancer

Questionnaire study to identify initial symptoms and processes leading up to diagnosis in metastatic breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032955
Enrollment
300
Registered
2023-11-09
Start date
2023-12-21
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50.9

Interventions

Group 1: All patients included in the study will receive a one-time questionnaire, which will be filled out in the presence of a person appointed by the study director. Data acquisition is expected to

Sponsors

Universitätsfrauenklinik Ulm
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with metastatic breast cancer who are affiliated to the Ulm University Women's Clinic are to be included.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Primary endpoints of this study will be: • the symptom burden prior to the diagnosis of metastatic breast cancer • the latency between the appearance of initial disease-related symptoms and the diagnosis of metastatic breast cancer • the professional groups involved in the diagnosis process • the correlation between the computer tomographic tumor burden and the symptom burden The above-mentioned questions will be determined retrospectively through patient questionnaires and data from the patient file.

Secondary

MeasureTime frame
• patient adherence to pre- or post-treatment as well as patient participation • initiated examinations

Countries

Germany

Contacts

Public ContactHenning Schäffler

Universitätsfrauenklinik Ulm

henning.schaeffler@uniklinik-ulm.de+4973150058531

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026